Private Equity and Venture Capital Investment in the Global Pharmaceutical and Biotechnology Industry

Private Equity and Venture Capital Investment in the Global Pharmaceutical and Biotechnology Industry

Vigilance and Equanimity are the Needs of the Hour

RELEASE DATE
12-Feb-2014
REGION
Asia Pacific
Research Code: ND74-01-00-00-00
SKU: LS00119-AP-MR_16960

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
LS00119-AP-MR_16960

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This study for the private equity and venture capital trends in the global pharmaceutical and biotechnology industry analyzes the various deals in the industry. The deals are analyzed based on number and average value. The trends are also observed based on the geographic region and buyer types. The study delves into the nature of cross border deals and also keeps into account various deal multiples such as deal value and investment rounds. The distribution of deals across key therapeutic areas has been dealt to understand the focus of investors and to highlight the key therapeutic areas in the near future. The analysis also includes geography-wise interest of buyers in regions across other geographies in terms both deal value and volume.

Table of Contents

Executive Summary

Key Terms Used in the Study

Key Terms Used in the Study (continued)

Objectives of the Study

Research Objective and Scope

Research Objective and Scope (continued)

Research Methodology

Pharma and Biotech Industry—Stock Indices Performance

Reducing Profitability

Regulatory Challenges

Patent Expiry

Changing Role of Big Pharma

Overall HC Industry—PEVC Deal Trends by Volume

PEVC Deal Trends by Volume and Value

PEVC Deal Trends by Average Deal Value by Transaction Type

Volume and Value of PE Deal Trends by Sectors

PEVC Deals Involving Big Pharma

VC Deal Trends by Sectors

Pharmaceutical Sector—Stages of VC Investment Snapshot

Pharmaceutical Sector—Stages of VC Investment Average Deal Value Analysis

Biotechnology Sector—Stages of VC Investment Snapshot

Biotechnology Sector—Stages of Financing Deal Value Analysis

Deal Value Range Analysis—VC Investment

Deal Value Range Analysis—PE Investment

PEVC Deal Analysis Across Geographies

PEVC Deal Share Analysis Across Geographies

PEVC Deal Analysis in the North American Region

PEVC Deal Snapshot in the North American Region

PEVC Deal Analysis in the European Region

PEVC Deal Snapshot in European Region

PEVC Deal Analysis in the APAC Region

PEVC Deal Snapshot in APAC Region

Volume Analysis of IPO

Value Analysis of IPO

Value Analysis of IPO by Geography

PEVC Volume Analysis by Key Therapeutic Areas

PEVC Value Analysis by Key Therapeutic Areas

Five Big Conclusions

Legal Disclaimer

Who is Frost & Sullivan

What Makes Us Unique

TEAM Methodology

Our Global Footprint 40+ Offices

The global oncology drug delivery market (or oncolytics market) was worth $91.00 billion in 2013 and has been growing at an annual rate of 5.0%. The market, which includes drug delivery systems for cancer therapy and cancer pain, is expected to generate $100.96 billion in 2015. The oral drug delivery systems segment accounted for an estimated 25.0% of the total global market in 2013 and will continue to grow stronger in 2015. Currently, the injectable drug delivery system segment leads the cancer drug delivery market; however, nanoparticles (including micro-needles, patches, and orals) are expected to lead the market in the future. --BEGIN PROMO-- Analysis of the Global Oncology Drug Delivery Market
More Information
No Index Yes
Podcast No
Author Saneesh Edacherian
WIP Number ND74-01-00-00-00
Is Prebook No